Study design: Retrospective analysis. Objectives: To evaluate the ecacy of intrathecal baclofen (ITB) for upper extremity spastic hypertonia in tetraplegia of spinal origin. Setting: University of Alabama at Birmingham hospital. Methods: The medical records of 14 individuals with tetraplegia of spinal origin who underwent intrathecal baclofen pump placement were reviewed. The eects of intrathecal baclofen on spasm frequency, deep tendon re¯exes, and tone (Ashworth scale) were assessed for the upper and lower extremities for a 1-year follow-up period.
Introduction
Cervical injuries of the spinal cord frequently lead to hypertonia characterized by disabling spasticity and dystonia involving the upper and lower extremities. In this setting, spasticity is de®ned as a velocityexaggerated increase in tonic stretch re¯exes (muscle tone) resulting from hyperactivity of the stretch re¯ex.
1 ± 3 Acquired dystonia is a persistent attitude or posture of the extremities, such as an overextension or over¯exion of the hand, inversion of the foot, or torsion of the spine associated with twisting, lateral bending, or torsion of the back. 4 Severe cases of hypertonia can be refractory to commonly used oral medications including baclofen. In contrast, the intrathecal delivery of baclofen has been shown to be eective for refractory hypertonia due to a number of processes that cause spinal cord pathology. 5 ± 14 Baclofen, 4-amino-3 (p-chlorophenyl) butyric acid, is felt to work by binding to inhibitory presynaptic GABA-B receptors in the spinal cord. 1 Intrathecal delivery of the drug facilitates achievement of therapeutic levels in the cerebrospinal¯uid (CSF) while minimizing systemic side eects (ie, drowsiness or confusion). 1,5 ± 8 Prior studies examining the ecacy of intrathecal baclofen (ITB) for hypertonia of spinal origin have presented results solely on ecacy in the lower extremities.
5,6,9 ± 11 To our knowledge, there are no citations in the medical literature that provide objective evidence for the ecacy of intrathecal baclofen when treating upper extremity hypertonia of spinal origin. To address this issue, a retrospective analysis was performed to speci®cally examine and de®ne the magnitude of eect on upper extremity hypertonia secondary to spinal pathology.
The importance of catheter placement is also broached as the lumbar-to-cisternal CSF concentration for baclofen is 4.1 : 1 and, subsequently, the lack of reported results concerning upper extremity hypertonia could be due to the placement of pump catheters at lower thoracic/lumbar levels. 15 In the medical literature, pump catheters have been primarily reported as being placed in the intrathecal space between approximately T10 and L2, 5 ± 7,11 ± 13,16 although a few investigators have hinted at the importance of catheter placement with spinal cord pathology. 16 ± 18 In contrast to spasticity of spinal origin, midthoracic catheter placement for upper extremity hypertonia has been evaluated for traumatic brain injury and cerebral palsy, and subsequently found to be ecacious.
1,18 ± 21 From clinical observation, it was our impression that by threading the catheter cephalid to approximately the T6 level, one could achieve signi®cant reductions in upper extremity hypertonia in persons with spinal cord pathology as well.
Methods

Subjects
The medical records of patients who underwent baclofen pump placement from October 1995 to November 1999, under the auspices of the Departments of Physical Medicine and Rehabilitation and Neurosurgery at the University of Alabama at Birmingham, were reviewed. Patients with spinal cord pathology aicting the cervical segments (C1 ± T1) were selected for further analysis. This subset of patients consisted of 14 individuals. These 14 individuals comprised the study cohort. All study subjects had sustained their injuries at least 6 months prior to baclofen pump placement and had failed to respond to treatment with oral agents, including a trial of oral baclofen, or had experienced unacceptable side eects. Other characteristics of study subjects are summarized in Table 1 .
Screening procedure
All patients except two were screened via a bolus injection of 50 mg of intrathecal baclofen. A lumbar puncture was performed at either the L3 ± L4 or the L2 ± L3 interspace, and 1 cc (50 mg) of baclofen was injected. Data was collected and scored for spasm frequency, deep tendon re¯exes, and tone at 1, 2, 4 and 6 h postinjection by the same investigator. Consideration for continuous ITB delivery via programmable pump and intrathecal catheter were given to those who had: (1) a reduction in tone of at least two points on the Ashworth scale in the lower extremities averaged over at least four joint movements (hip abduction, knee extension, knee¯exion, and ankle dorsi¯exion); or (2) a reduction in the spasm frequency score of at least two points in one lower extremity without untoward side eects. The patients who had a partial response but did not meet criteria for pump placement were given the option of a 75 to 100 mg bolus trial. If they met criteria with the higher dose trial, pump placement was oered.
Pump implantation
The continuous infusion pump and intraspinal catheter system were implanted under general anesthesia with the patient in the lateral decubitus position. the programmable pump was placed in a lower abdominal wall subcutaneous pocket, above the rectus fascia. The catheter was placed into the lumbar subarachnoid space via a percutaneous technique using a 14-or 15-gauge Touhy needle. The catheter, which was premeasured before insertion, was threaded up to the midthoracic (T6) area because all patients had hypertonia that involved the upper extremities. The intraspinal catheter was then tunneled in the subcutaneous space to the programmable pump, completing the procedure. Postoperatively all patients received 24 to 36 h of intravenous vancomycin and gentamicin for infection prophylaxis. Outcome measures and follow-up Prior to pump placement the study subjects had undergone a baseline evaluation, and following pump placement they were re-evaluated at approximately 1, 3, 6, 9 and 12 months. Tone, spasm frequency, and deep tendon re¯exes were assessed at baseline and at each subsequent follow-up interval. Tone was measured in the upper extremities (shoulder abduction, elbow¯exion, elbow extension, wrist extension) and lower extremities (hip abduction, knee¯exion, knee extension, ankle dorsi¯exion) using the 5-point Ashworth scale (Table 2 ). Spasm frequency was recorded in the upper extremities and lower extremities using a 5-point scale ( Table 2 ). Deep tendon re¯exes at the biceps, patella, and Achilles were documented with a 6-point scale (Table 2) . At each evaluation, the current 24-h (daily) infused dosage of baclofen was recorded. If indicated, dosage adjustments were made in 10% to 20% increments. Also noted were untoward complications, including cognitive dysfunction, urologic problems, infections, and problems regarding physical and occupational therapy, as well as equipment malfunction.
Statistical analysis
Changes in muscle tone, spasms, and deep tendon re¯exes were analyzed using Friedman's test. This was utilized because the muscle tone, spasm, and re¯ex scores used nonparametric, ordinal level scales, and the Friedman's test is felt to be the nonparametric equivalent of a repeated measures analysis of variance (ANOVA) with a single group. 22 The Wilcoxon signed rank test was also employed to test the signi®cance of observed dierences between speci®c time points during the follow-up period. A value of P50.05 was considered signi®cant. Although nonparametric tests were used, data are presented as averages and standard deviations (SD) to facilitate the interpretation of the magnitude and clinical signi®cance of the results. In addition, for clarity of presentation, rather than reporting tone, spasm, and re¯ex scores for individual muscles (ie, deltoids, biceps, triceps, etc.), muscles tested for the upper extremities were averaged. Similarly, scores for the lower extremities were averaged as well. Statistical analysis was then performed separately for the upper and lower extremities.
The reliability and reproducibility of the Ashworth scale, spasm frequency scale, and re¯ex scale have previously been described. 19, 23, 24 Statistical analysis was performed utilizing StatView 5.0 (Abacus Concept Inc., Berkeley, CA, USA).
Results
Lower extremities
Following baclofen pump placement, the average Ashworth score (tone) for the lower extremities decreased from 3.1+1.3 (SD) at baseline to 1.7+0.9 (SD) at 12 months (P50.0001, Friedman) (Figure 1) . Similarly, the average spasm score decreased from 3.3+0.9 (SD) at baseline to 1.8+1.5 (SD) at 12 months (P=0.0011, Friedman) ( Figure 2 ). Re¯exes also decreased signi®cantly. The average baseline re¯ex score was 2.8+1.3 (SD) compared to 0.4+0.9 (SD) at 12 months (P50.0001, Friedman) ( Figure 3 ).
Upper extremities
Similar to the lower extremities, there was a signi®cant decline in upper extremity hypertonia during the 12 month follow-up period. The average baseline Ashworth score was 2.4+1.1 (SD) com- Figure 5 ). The dierence was signi®cant (P=0.0012) using the less rigorous Wilcoxon signed rank test. The Wilcoxon signed rank test compared the baseline value and ®nal value (12 months) unlike the Friedman's test which assessed the curve throughout the follow-up period. For upper extremity re¯exes, the average baseline re¯ex score was 2.3+0. 
Complications
Pump placement was well tolerated by all the patients and there were no signi®cant complications during the 12-month follow-up period. There were no reported cognitive side eects, related seizure breakthroughs, or changes in urinary or fecal voiding patterns. One patient did develop a pocket infection approximately 20 months after pump placement which necessitated surgical replacement, however, this occurred outside the 1-year study follow-up period.
Discussion
Eects on hypertonia The ecacy of intrathecal baclofen has been clearly demonstrated for refractory hypertonia resulting from a variety of pathologic conditions. 1,5 ± 10,18,21,25 ± 32 Furthermore, intrathecal baclofen has been shown to have an eect on hypertonia in the upper and lower extremities due to supratentorial pathology such as acquired brain injury and cerebral palsy. 1,18 ± 21,28 In contrast, the presence and magnitude of tone reduction has yet to be con®rmed and de®ned for upper extremity hypertonia of spinal origin.
This study is the ®rst to document a statistically signi®cant decrease in Ashworth (tone) and re¯ex scores in upper extremity hypertonia due to pathology at the level of the spinal cord. Upper extremity Ashworth scores improved from 2.4+1.1 (SD) at baseline to 1.8+1.0 (SD) at 12 months. In comparison, lower extremity Ashworth scores improved from 3.1+1.3 (SD) at baseline to 1.7+0.9 (SD) at 12 months.
The relative dierence in magnitude of improvement when comparing the upper extremities to the lower extremities could partially be explained by greater baseline spasticity in the lower extremities. Because of this, there was more room for improvement in the lower extremities compared to the upper extremities. This rationale is reinforced when 12 month Ashworth scores are directly compared in the upper and lower extremities (1.8+1.0 SD vs 1.7+0.9 SD). When this is done, one can see that severity of tone in the upper and lower extremities, measured with Ashworth scores, is comparable at 12 months. Similar ®ndings have been noted in the traumatic brain injury and pediatric cerebral palsy populations. 1, 18 There was not, however, a signi®cant decline in spasm frequency with the relatively rigorous Friedman's test. Friedman's test takes into account the shape of the curve during the entire follow-up period, while the Wilcoxon signed rank test examines the magnitude of dierence between two de®ned timepoints on the curve. With the less rigorous Wilcoxon, a signi®cant (P=0.0012) dierence in spasm frequency was noted between the initial evaluation and the 12-month evaluation. This is probably the result of several factors. First, the spasm frequency score was dependent on verbal feedback from the patient while the tone and re¯exes were objectively measured by the examiner. Secondly, after the initial decline in spasm frequency from initial evaluation to 1 month evaluation ( Figure 5 ), the baseline oscillated. Again, this was probably impacted by patient diculty in accurately distinguishing between scores on the lower end of the spasm frequency scale. Also, patient numbers might have been insucient and therefore prevented the decline from reaching statistical signi®cance with Friedman's test. Perhaps most importantly, patients were selected predominantly for disabling lower extremity tone or spasms which may have resulted in a¯oor eect. The data supports this as the initial tone and spasm frequency scores were much lower in the upper extremities, 2.4 and 2.3 respectively, vs 3.1 and 3.3. in the lower extremities.
Like prior studies, our study con®rmed the ecacy of intrathecal baclofen for the treatment of refractory lower extremity hypertonia.
1,5 ± 10,18,21,25 ± 32 There were statistically signi®cant decreases in lower extremity tone, spasm frequency, and hyperre¯exia following the initiation of therapy with intrathecal baclofen, and the eects persisted for the 12-month follow-up period.
Another interesting ®nding is that when the upper and lower extremity curves for Ashworth (tone) scores are closely scrutinized, there appears to be a slight increase in tone at 12 months in comparison to the intervening months. This suggests the possible development of early tolerance to intrathecal baclofen. It would be of interest to follow patients for extended periods (412 months) to see if drug tolerance becomes more of an issue.
It should also be emphasized that patients in this study had their intrathecal catheters threaded to T6 which is signi®cantly higher than what has been traditionally advocated (T10 ± L2). 5 ± 7,11 ± 13,16 This is important because intrathecal baclofen diuses rapidly from the intrathecal space into the spinal cord, resulting in a lumbar-to-brain gradient. 1, 6, 16 Since intrathecal delivered baclofen crosses from the Prior attempts to address upper extremity hypertonia by increasing the rate of infusion have resulted in lower extremity hypotonia and functional losses with regards to transfers and activities of daily living. 5 Moving the catheter cephalid could theoretically improve the ecacy of intrathecal baclofen for upper extremity hypertonia by increasing CSF drug concentrations in the upper thoracic and cervical regions. Our study ®ndings appear to support this and are in agreement with what has been previously noted in the traumatic brain injury and cerebral palsy populations. 1,18 ± 21 This deviation from standard procedure was well tolerated by our patients as there were no adverse events in the study population attributable to the change in catheter location.
Therefore, intrathecal baclofen appears to be an eective intervention for upper extremity as well as lower extremity hypertonia of spinal origin. Furthermore, ecacy for upper extremity hypertonia appears to be facilitated by midthoracic (T6) catheter placement. This deviation from traditional catheter placement (T10 ± L2) was well tolerated and there were no signi®cant complications in our study population.
Dosage requirements
Dosage requirements showed an almost linear increase throughout the 12 month follow-up period. Other investigators have also described a linear relationship. 33 It is our belief that this relationship is secondary to dosage adjustments to optimize ecacy following pump placement along with increasing drug tolerance. Prior studies with intrathecal baclofen have also noted increasing dosage requirements with the passage of time. 1, 5, 8, 33 This has been attributed to the downregulation of GABA-B receptors at the spinal level. 1, 33 In our study, the slight increase in tone at 12 months is also suggestive of emerging tolerance. Akman found a signi®cant increase in dosage requirements up until 12 months followed by a leveling o from 12 to 24 months. 33 Others have also suggested a plateauing eect. 10, 11, 13 When progressive tolerance has become an issue, it has been successfully treated with`drug holidays'. 8,11 ± 13 In these cases, intrathecal saline or opiates were substituted for baclofen which was later successfully restarted at lower doses.
Therefore, physiologic tolerance does appear to be a real issue during the ®rst year but there is evidence that dosage requirements thereafter stabilize. 33 In order to clarify this issue and its clinical implications, additional long-term (412 months) studies are needed. This should become a reality as the numbers of patients increase and we continue to gain experience with the use of intrathecal baclofen.
Summary
This study demonstrates that signi®cant reductions in upper extremity hypertonia of spinal origin can be safely achieved using intrathecal baclofen with midthoracic (T6) catheter placement. Improvement can be documented using Ashworth, re¯ex, and spasm frequency scores for both the upper and lower extremities. Additional studies are needed that examine the eect of improved upper extremity spasticity and dystonia on functional status. Regardless, reductions in hypertonia can ameliorate pain, improve sleep, and facilitate nursing care and hygiene. The natural history of drug tolerance after 1 year and its possible impact on the long-term (412 months) ecacy of intrathecal baclofen also awaits clari®cation.
